Canopy Growth Q3 FY2024 revenue $78.5M; adjusted EBITDA loss narrows 82% to $9M

Canopy Growth Corp

2023-Q3 EPS reported -$8.08 revenue$224,358,000

Net revenue $78.5M, down 7% YoY; net loss from continuing operations $230.3M.
Adjusted EBITDA loss $9.0M, improving 82% from $50M loss in Q3 FY2023.
Canada medical cannabis revenue record $15.6M (+11% YoY); Canada B2B adult-use revenue up 9%.
Cash and short-term investments $186M; debt reduced by $69M during quarter.
Canopy USA special meeting set for April 12, 2024; board appoints two new directors.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Canopy Growth Corp reported fiscal third quarter ended December 31, 2023 results: revenue $79MM, net income $(230.3). Guidance reaffirmed.

Period: fiscal third quarter ended December 31, 2023
Revenue: $79MM
Net income: $(230.3)
Guidance: reaffirmed
Result: reported results

Exact text from the filing

divestiture of the Canada national retail business in Q3 FY2023, Q3 FY2024 consolidated net revenue grew by 6% year-over-year. Delivered Q3 FY2024 consolidated net revenue of $79MM representing a decline of 7% year-over-year. • Rest-of-World cannabis revenue in Q3 FY2024 increased 81% year-over-year, led by continued strong growth in Australia, return to

View on SEC.gov

12 earnings releases filed in the last 30 days. Browse all earnings releases →

Canopy Growth Corp filing history →

Source: SEC EDGAR

accession 0000950170-24-013050

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.